FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 1999;341(21):1632.

Previous Volume 340:197-206 January 21, 1999 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article PubMed Citation

In 1979 and 1980, the chemical structures of the material previously known as slow-reacting substance of anaphylaxis were elucidated as 5(S)- hydroxy- 6(R)-glutathionyl- 7,9-trans-11,14- cis - eico- satetraenoic acid¹ and its cysteinyl-glycyl and cysteinyl congener (also known as leukotrienes C₄, D₄, and E₄, respectively). These molecules were so named because the parent molecule was originally isolated from leukocytes, and its carbon backbone contained three double bonds in series, which constitutes a triene. This structural information provided the key to the oxidative pathway of lipid metabolism known as the 5-lipoxygenase pathway.

One of the chief reasons . . . [Full Text of this Article]

The 5-Lipoxygenase Pathway

Leukotriene Receptors

Prevention of Induced Asthma

Allergen-Induced Asthma

Exercise and Cold-Air Hyperventilation

Aspirin-Induced Asthma

Treatment of Chronic Persistent Asthma

Short-Term Bronchodilator Effects

Improvement in Airway Function in Chronic Persistent Asthma

Use of ß-Adrenergic Agonists and Symptom Scores

Requirement for Glucocorticoid Therapy and Markers of Inflammation

Leukotriene Modifiers as Compared with Other Antiasthma Drugs

Safety

Routine Therapy with Drugs That Act on the 5-Lipoxygenase Pathway in Clinical Asthma

Conclusions

Source Information

From the Partners Asthma Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (J.M.D., E.I.); and the Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ont., Canada (P.M.O.).

Address reprint requests to Dr. Drazen at the Respiratory Disease Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.

References

This article has been cited by other articles:

• Robinson, A. J., Kashanin, D., O'Dowd, F., Williams, V., Walsh, G. M. (2008). Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT1R antagonism. J. Leukoc. Biol. 83: 1522-1529 [Abstract] [Full Text]  
• Joos, S, Miksch, A, Szecsenyi, J, Wieseler, B, Grouven, U, Kaiser, T, Schneider, A (2008). Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 63: 453-462 [Abstract] [Full Text]  
• Wung, S.-F., Aouizerat, B. E. (2008). Candidate Genes of the 5-Lipoxygenase Pathway in Acute Coronary Syndrome: A Pilot Study. Biol Res Nurs 9: 280-292 [Abstract]  
• Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., Pizzichini, E., Sullivan, S. D., Wenzel, S. E., Zar, H. J. (2008). Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31: 143-178 [Abstract] [Full Text]  
• Coffey, M. J., Serezani, C. H., Phare, S. M., Flamand, N., Peters-Golden, M. (2007). NADPH oxidase deficiency results in reduced alveolar macrophage 5-lipoxygenase expression and decreased leukotriene synthesis. J. Leukoc. Biol. 82: 1585-1591 [Abstract] [Full Text]  
• Peters-Golden, M., Henderson, W. R. Jr. (2007). Leukotrienes. NEJM 357: 1841-1854 [Full Text]  
• Wechsler, M. E., Shepard, J.-A. O., Mark, E. J. (2007). Case 15-2007 -- A 20-Year-Old Woman with Asthma and Cardiorespiratory Arrest. NEJM 356: 2083-2091 [Full Text]  
• Chang, W.-C., Nelson, C., Parekh, A. B. (2006). Ca2+ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells. FASEB J. 20: 2381-2383 [Abstract] [Full Text]  
• Kelly, M. M., Chakir, J., Vethanayagam, D., Boulet, L.-P., Laviolette, M., Gauldie, J., O'Byrne, P. M. (2006). Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge.. Chest 130: 741-753 [Abstract] [Full Text]  
• Bonetto, G., Corradi, M., Carraro, S., Zanconato, S., Alinovi, R., Folesani, G., Da Dalt, L., Mutti, A., Baraldi, E. (2006). Longitudinal Monitoring of Lung Injury in Children after Acute Chlorine Exposure in a Swimming Pool. Am. J. Respir. Crit. Care Med. 174: 545-549 [Abstract] [Full Text]  
• de Benedictis, F. M., del Giudice, M. M., Forenza, N., Decimo, F., de Benedictis, D., Capristo, A. (2006). Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 28: 291-295 [Abstract] [Full Text]  
• Shim, Y. M., Zhu, Z., Zheng, T., Lee, C. G., Homer, R. J., Ma, B., Elias, J. A. (2006). Role of 5-Lipoxygenase in IL-13-Induced Pulmonary Inflammation and Remodeling. J. Immunol. 177: 1918-1924 [Abstract] [Full Text]  
• Du, L., Zhang, Z., Luo, X., Chen, K., Shen, X., Jiang, H. (2006). Binding Investigation of Human 5-Lipoxygenase with Its Inhibitors by SPR Technology Correlating with Molecular Docking Simulation.. J Biochem 139: 715-723 [Abstract] [Full Text]  
• Lima, J. J., Zhang, S., Grant, A., Shao, L., Tantisira, K. G., Allayee, H., Wang, J., Sylvester, J., Holbrook, J., Wise, R., Weiss, S. T., Barnes, K. (2006). Influence of Leukotriene Pathway Polymorphisms on Response to Montelukast in Asthma. Am. J. Respir. Crit. Care Med. 173: 379-385 [Abstract] [Full Text]  
• Gyllfors, P, Kumlin, M, Dahlen, S-E, Gaber, F, Ehrs, P-O, Dahlen, B (2005). Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax 60: 902-908 [Abstract] [Full Text]  
• Busse, W. W., Wanner, A., Adams, K., Reynolds, H. Y., Castro, M., Chowdhury, B., Kraft, M., Levine, R. J., Peters, S. P., Sullivan, E. J. (2005). Investigative Bronchoprovocation and Bronchoscopy in Airway Diseases. Am. J. Respir. Crit. Care Med. 172: 807-816 [Abstract] [Full Text]  
• Casas, A., Gomez, F. P., Dahlen, B., Roca, J., Barbera, J. A., Dahlen, S-E., Rodriguez-Roisin, R. (2005). Leukotriene D4-induced hypoxaemia in asthma is mediated by the cys-leukotriene1 receptor. Eur Respir J 26: 442-448 [Abstract] [Full Text]  
• Garcia Garcia, M. L., Wahn, U., Gilles, L., Swern, A., Tozzi, C. A., Polos, P. (2005). Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study. Pediatrics 116: 360-369 [Abstract] [Full Text]  
• Chu, E. K., Drazen, J. M. (2005). Asthma: One Hundred Years of Treatment and Onward. Am. J. Respir. Crit. Care Med. 171: 1202-1208 [Abstract] [Full Text]  
• Kwong, K., Lee, L.-Y. (2005). Prostaglandin E2 potentiates a TTX-resistant sodium current in rat capsaicin-sensitive vagal pulmonary sensory neurones. J. Physiol. 564: 437-450 [Abstract] [Full Text]  
• Comhair, S. A.A., Xu, W., Ghosh, S., Thunnissen, F. B.J.M., Almasan, A., Calhoun, W. J., Janocha, A. J., Zheng, L., Hazen, S. L., Erzurum, S. C. (2005). Superoxide Dismutase Inactivation in Pathophysiology of Asthmatic Airway Remodeling and Reactivity. Am. J. Pathol. 166: 663-674 [Abstract] [Full Text]  
• Murai, A., Abe, M., Hayashi, Y., Sakata, N., Katsuragi, T., Tanaka, K. (2005). Comparison Study between the Mechanisms of Allergic Asthma Amelioration by a Cysteinyl-Leukotriene Type 1 Receptor Antagonist Montelukast and Methylprednisolone. J. Pharmacol. Exp. Ther. 312: 432-440 [Abstract] [Full Text]  
• Hui, Y., Cheng, Y., Smalera, I., Jian, W., Goldhahn, L., FitzGerald, G. A., Funk, C. D. (2004). Directed Vascular Expression of Human Cysteinyl Leukotriene 2 Receptor Modulates Endothelial Permeability and Systemic Blood Pressure. Circulation 110: 3360-3366 [Abstract] [Full Text]  
• Okunishi, K., Dohi, M., Nakagome, K., Tanaka, R., Yamamoto, K. (2004). A Novel Role of Cysteinyl Leukotrienes to Promote Dendritic Cell Activation in the Antigen-Induced Immune Responses in the Lung. J. Immunol. 173: 6393-6402 [Abstract] [Full Text]  
• Lee, D.K.C., Haggart, K., Robb, F.M., Lipworth, B.J. (2004). Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 24: 226-230 [Abstract] [Full Text]  
• Lee, D K C, Green, S A (2004). Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy. Thorax 59: 727-727 [Full Text]  
• Snider, G. L. (2004). Only Cell and Molecular Biology Can Lead to an Understanding of Pathogenesis of Lung Disease. Am. J. Respir. Crit. Care Med. 170: i-ii [Full Text]  
• Cap, P, Chladek, J, Pehal, F, Maly, M, Petru, V, Barnes, P J, Montuschi, P (2004). Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax 59: 465-470 [Abstract] [Full Text]  
• Mendes, E. S., Campos, M. A., Hurtado, A., Wanner, A. (2004). Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma. Am. J. Respir. Crit. Care Med. 169: 1131-1134 [Abstract] [Full Text]  
• Yang, G., Haczku, A., Chen, H., Martin, V., Galczenski, H., Tomer, Y., Van Beisen, C. R., Evans, J. F., Panettieri, R. A., Funk, C. D. (2004). Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L992-L1001 [Abstract] [Full Text]  
• Mandal, A. K., Skoch, J., Bacskai, B. J., Hyman, B. T., Christmas, P., Miller, D., Yamin, T.-t. D., Xu, S., Wisniewski, D., Evans, J. F., Soberman, R. J. (2004). The membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. USA 101: 6587-6592 [Abstract] [Full Text]  
• Machida, I., Matsuse, H., Kondo, Y., Kawano, T., Saeki, S., Tomari, S., Obase, Y., Fukushima, C., Kohno, S. (2004). Cysteinyl Leukotrienes Regulate Dendritic Cell Functions in a Murine Model of Asthma. J. Immunol. 172: 1833-1838 [Abstract] [Full Text]  
• Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., Mehrabian, M. (2004). Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. NEJM 350: 29-37 [Abstract] [Full Text]  
• Serhan, C. N., Jain, A., Marleau, S., Clish, C., Kantarci, A., Behbehani, B., Colgan, S. P., Stahl, G. L., Merched, A., Petasis, N. A., Chan, L., Van Dyke, T. E. (2003). Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators. J. Immunol. 171: 6856-6865 [Abstract] [Full Text]  
• Ishiwara, M., Aoki, Y., Takagaki, H., Ui, M., Okajima, F. (2003). TA-270 [4-Hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an Anti-Asthmatic Agent, Inhibits Leukotriene Production Induced by IgE Receptor Stimulation in RBL-2H3 Cells. J. Pharmacol. Exp. Ther. 307: 583-588 [Abstract] [Full Text]  
• Bjermer, L., Bisgaard, H., Bousquet, J., Fabbri, L. M, Greening, A. P, Haahtela, T., Holgate, S. T, Picado, C., Menten, J., Dass, S B., Leff, J. A, Polos, P. G (2003). Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327: 891- [Abstract] [Full Text]  
• (2003). Workshop on Lung Disease and the Environment: Where Do We Go from Here?. Am. J. Respir. Crit. Care Med. 168: 250-254 [Full Text]  
• Zaitsu, M., Hamasaki, Y., Tsuji, K., Matsuo, M., Fujita, I., Aoki, Y., Ishii, E., Kohashi, O. (2003). Dexamethasone accelerates catabolism of leukotriene C4 in bronchial epithelial cells. Eur Respir J 22: 35-42 [Abstract] [Full Text]  
• Tang, M. B. Y., Yosipovitch, G. (2003). Acute Churg-Strauss Syndrome in an Asthmatic Patient Receiving Montelukast Therapy. Arch Dermatol 139: 715-718 [Full Text]  
• Elias, J. A., Lee, C. G., Zheng, T., Shim, Y., Zhu, Z. (2003). Interleukin-13 and Leukotrienes: An Intersection of Pathogenetic Schema. Am. J. Respir. Cell Mol. Bio. 28: 401-404 [Full Text]  
• Ducharme, F. M (2003). Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 326: 621-621 [Abstract] [Full Text]  
• Vaquerizo, M J, Casan, P, Castillo, J, Perpina, M, Sanchis, J, Sobradillo, V, Valencia, A, Verea, H, Viejo, J L, Villasante, C, Gonzalez-Esteban, J, Picado, C (2003). Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58: 204-210 [Abstract] [Full Text]  
• Drazen, J. M. (2003). Asthma and the Human Genome Project: Summary of the 45th Annual Thomas L. Petty Aspen Lung Conference. Chest 123: 447S-449S [Full Text]  
• Tedla, N., Bandeira-Melo, C., Tassinari, P., Sloane, D. E., Samplaski, M., Cosman, D., Borges, L., Weller, P. F., Arm, J. P. (2003). Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc. Natl. Acad. Sci. USA 100: 1174-1179 [Abstract] [Full Text]  
• Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., Moos, M. P. W., Kaiser, B., Cohnert, T. U., Wahlers, T., Zieske, A., Plenz, G., Robenek, H., Salbach, P., Kuhn, H., Radmark, O., Samuelsson, B., Habenicht, A. J. R. (2003). Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. USA 100: 1238-1243 [Abstract] [Full Text]  
• Phipps, P, Garrard, C S (2003). The pulmonary physician in critical care * 12: Acute severe asthma in the intensive care unit. Thorax 58: 81-88 [Abstract] [Full Text]  
• Sousa, A. R., Parikh, A., Scadding, G., Corrigan, C. J., Lee, T. H. (2002). Leukotriene-Receptor Expression on Nasal Mucosal Inflammatory Cells in Aspirin-Sensitive Rhinosinusitis. NEJM 347: 1493-1499 [Abstract] [Full Text]  
• Kanniess, F., Richter, K., Janicki, S., Schleiss, M.B., Jorres, R.A., Magnussen, H. (2002). Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J 20: 1080-1087 [Abstract] [Full Text]  
• Terashima, T., Amakawa, K., Matsumaru, A., Yamaguchi, K. (2002). Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor. Chest 122: 1566-1570 [Abstract] [Full Text]  
• Leigh, R., Vethanayagam, D., Yoshida, M., Watson, R. M., Rerecich, T., Inman, M. D., O'Byrne, P. M. (2002). Effects of Montelukast and Budesonide on Airway Responses and Airway Inflammation in Asthma. Am. J. Respir. Crit. Care Med. 166: 1212-1217 [Abstract] [Full Text]  
• Ghiro, L., Zanconato, S., Rampon, O., Piovan, V., Pasquale, M.F., Baraldi, E. (2002). Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20: 630-634 [Abstract] [Full Text]  
• Palmer, L. J., Silverman, E. S., Weiss, S. T., Drazen, J. M. (2002). Pharmacogenetics of Asthma. Am. J. Respir. Crit. Care Med. 165: 861-866 [Full Text]  
• Rorke, S, Jennison, S, Jeffs, J A, Sampson, A P, Arshad, H, Holgate, S T (2002). Role of cysteinyl leukotrienes in adenosine 5`-monophosphate induced bronchoconstriction in asthma. Thorax 57: 323-327 [Abstract] [Full Text]  
• Minoguchi, K., Kohno, Y., Minoguchi, H., Kihara, N., Sano, Y., Yasuhara, H., Adachi, M. (2002). Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast. Chest 121: 732-738 [Abstract] [Full Text]  
• Zeldin, D. C. (2002). The 5-Lipoxygenase Pathway . A New Therapeutic Target for the Treatment of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 165: 146-147 [Full Text]  
• PETERS-GOLDEN, M., BAILIE, M., MARSHALL, T., WILKE, C., PHAN, S. H., TOEWS, G. B., MOORE, B. B. (2002). Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice. Am. J. Respir. Crit. Care Med. 165: 229-235 [Abstract] [Full Text]  
• DAHLEN, S.-E., MALMSTROM, K., NIZANKOWSKA, E., DAHLEN, B., KUNA, P., KOWALSKI, M., LUMRY, W. R., PICADO, C., STEVENSON, D. D., BOUSQUET, J., PAUWELS, R., HOLGATE, S. T., SHAHANE, A., ZHANG, J., REISS, T. F., SZCZEKLIK, A. (2002). Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial. Am. J. Respir. Crit. Care Med. 165: 9-14 [Abstract] [Full Text]  
• Obase, Y., Shimoda, T., Tomari, S.-y., Mitsuta, K., Kawano, T., Matsuse, H., Kohno, S. (2002). Effects of Pranlukast on Chemical Mediators in Induced Sputum on Provocation Tests in Atopic and Aspirin-Intolerant Asthmatic Patients. Chest 121: 143-150 [Abstract] [Full Text]  
• Roman, R. J. (2002). P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function. Physiol. Rev. 82: 131-185 [Abstract] [Full Text]  
• Kerstjens, H. A M, Groen, H. J, van der Bij, W. (2001). Recent advances: Respiratory medicine. BMJ 323: 1349-1353 [Full Text]  
• SEYMOUR, M. L., RAK, S., ABERG, D., RIISE, G. C., PENROSE, J. F., KANAOKA, Y., AUSTEN, K. F., HOLGATE, S. T., SAMPSON, A. P. (2001). Leukotriene and Prostanoid Pathway Enzymes in Bronchial Biopsies of Seasonal Allergic Asthmatics. Am. J. Respir. Crit. Care Med. 164: 2051-2056 [Abstract] [Full Text]  
• Naureckas, E. T., Solway, J. (2001). Mild Asthma. NEJM 345: 1257-1262 [Full Text]  
• Coffey, M. J., Phare, S. M., Peters-Golden, M. (2001). Peroxynitrite-Induced Nitrotyrosination of Proteins Is Blocked by Direct 5-Lipoxygenase Inhibitor Zileuton. J. Pharmacol. Exp. Ther. 299: 198-203 [Abstract] [Full Text]  
• Knorr, B., Franchi, L. M., Bisgaard, H., Vermeulen, J. H., LeSouef, P., Santanello, N., Michele, T. M., Reiss, T. F., Nguyen, H. H., Bratton, D. L. (2001). Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years. Pediatrics 108: e48-48 [Abstract] [Full Text]  
• Fish, J. E., Israel, E., Murray, J. J., Emmett, A., Boone, R., Yancey, S. W., Rickard, K. A. (2001). Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy. Chest 120: 423-430 [Abstract] [Full Text]  
• Rabe, K.F., Schmidt, D.T. (2001). Pharmacological treatment of asthma today. Eur Respir J 18: 34S-40s [Abstract] [Full Text]  
• Smith, G. C.S., Wu, W. X., Nathanielsz, P. W. (2001). Lipoxygenase gene expression in baboon intrauterine tissues in late pregnancy and parturition. Mol Hum Reprod 7: 587-594 [Abstract] [Full Text]  
• Serhan, C. N., Devchand, P. R. (2001). Novel Antiinflammatory Targets for Asthma . A Role for PPARgamma ?. Am. J. Respir. Cell Mol. Bio. 24: 658-661 [Full Text]  
• Salvi, S. S., Krishna, M. T., Sampson, A. P., Holgate, S. T. (2001). The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma. Chest 119: 1533-1546 [Abstract] [Full Text]  
• Kay, A.B. (2001). Allergy and Allergic Diseases- First of Two Parts. NEJM 344: 30-37 [Full Text]  
• Jacobs, E. R., Zeldin, D. C. (2001). The lung HETEs (and EETs) up. Am. J. Physiol. Heart Circ. Physiol. 280: H1-H10 [Abstract] [Full Text]  
• Gronert, K., Martinsson-Niskanen, T., Ravasi, S., Chiang, N., Serhan, C. N. (2001). Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses. Am. J. Pathol. 158: 3-9 [Abstract] [Full Text]  
• Reinus, J. F., Persky, S., Burkiewicz, J. S., Quan, D., Bass, N. M., Davern, T. J. (2000). Severe Liver Injury after Treatment with the Leukotriene Receptor Antagonist Zafirlukast. ANN INTERN MED 133: 964-968 [Abstract] [Full Text]  
• Malaviya, R., Chen, C.-L., Navara, C., Malaviya, R., Liu, X.-P., Keenan, M., Waurzyniak, B., Uckun, F. M. (2000). Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J. Pharmacol. Exp. Ther. 295: 912-926 [Abstract] [Full Text]  
• Dempsey, O J (2000). Leukotriene receptor antagonist therapy. Postgrad. Med. J. 76: 767-773 [Abstract] [Full Text]  
• Babu, K. S., Salvi, S. S. (2000). Aspirin and Asthma. Chest 118: 1470-1476 [Abstract] [Full Text]  
• Coffey, M. J., Phare, S. M., Peters-Golden, M. (2000). Prolonged Exposure to Lipopolysaccharide Inhibits Macrophage 5-Lipoxygenase Metabolism Via Induction of Nitric Oxide Synthesis. J. Immunol. 165: 3592-3598 [Abstract] [Full Text]  
• Schiavino, D, Nucera, E, Milani, A, Del Ninno, M, Buonomo, A, Sun, J, Patriarca, G (2000). The aspirin disease. Thorax 55: 66S-69 [Full Text]  
• Arm, J. P., Mark, E. J. (2000). Case 30-2000- A 25-Year-Old Man with Asthma, Cardiac Failure, Diarrhea, and Weakness of the Right Hand. NEJM 343: 953-961 [Full Text]  
• TSANG, F., FRED WONG, W. S. (2000). Inhibitors of Tyrosine Kinase Signaling Cascade Attenuated Antigen Challenge of Guinea-Pig Airways In Vitro. Am. J. Respir. Crit. Care Med. 162: 126-133 [Abstract] [Full Text]  
• Geller, M. (2000). Marked Peripheral Edema Associated with Montelukast and Prednisone. ANN INTERN MED 132: 924-924 [Full Text]  
• HASDAY, J. D., MELTZER, S. S., MOORE, W. C., WISNIEWSKI, P., RICHARD HEBEL, J., LANNI, C., DUBÉ, L. M., BLEECKER, E. R. (2000). Anti-inflammatory Effects of Zileuton in a Subpopulation of Allergic Asthmatics. Am. J. Respir. Crit. Care Med. 161: 1229-1236 [Abstract] [Full Text]  
• Strube, G., Rudolf, M. (2000). For and against: Should steroids be the first line treatment for asthma? • For • Against. BMJ 320: 47-49 [Full Text]  
• LAING, I. A., HERMANS, C., BERNARD, A., BURTON, P. R., GOLDBLATT, J., LE SOUËF, P. N. (2000). Association between Plasma CC16 Levels, the A38G Polymorphism, and Asthma. Am. J. Respir. Crit. Care Med. 161: 124-127 [Abstract] [Full Text]  
• Harding, S. M. (1999). The Dull-Edged Sword of Inhaled Corticosteroids. Chest 116: 854-856 [Full Text]  
• BISGAARD, H., LOLAND, L., ØJ, J. A. (1999). NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast. Am. J. Respir. Crit. Care Med. 160: 1227-1231 [Abstract] [Full Text]  
• Brash, A. R. (1999). Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate. J. Biol. Chem. 274: 23679-23682 [Full Text]  
• Schwarz, K., Walther, M., Anton, M., Gerth, C., Feussner, I., Kuhn, H. (2001). Structural Basis for Lipoxygenase Specificity. CONVERSION OF THE HUMAN LEUKOCYTE 5-LIPOXYGENASE TO A 15-LIPOXYGENATING ENZYME SPECIES BY SITE-DIRECTED MUTAGENESIS. J. Biol. Chem. 276: 773-779 [Abstract] [Full Text]  
• Ichinose, F., Zapol, W. M., Sapirstein, A., Ullrich, R., Tager, A. M., Coggins, K., Jones, R., Bloch, K. D. (2001). Attenuation of Hypoxic Pulmonary Vasoconstriction by Endotoxemia Requires 5-Lipoxygenase in Mice. Circ. Res. 88: 832-838 [Abstract] [Full Text]